Disclosed is a method for preparing an insulin glargine (GlyA 21 -Arg B31 -Ary B32 - human insulin) crystal, comprising crystallizing the insulin glargine at pH 7.0-9.0 and in a crystallization solution containing a recombinant insulin glargine, an organic solvent of a 10-30% concentration by volume, a zinc compound, a phenol derivative, a salt and an organic acid.

Patent No. 602541 Disclosed is an aqueous pharmaceutical formulation comprising 300 U/mL [equimolar to 300 IU human insulin] of insulin glargine.

The disclosure relates to a process of obtaining a fully folded two chain insulin glargine that require no further processing to make it functionally active. The present disclosure discloses a surprising effect of over expression of Kex2p intracellularly under the control of inducible FLD1 promoter in the host Pichia pastoris to produce two chain functional glargine secreted directly in the medium. The schematic digram of how the two chains are made inside the host Pichia pastoris and secretes i...

The present invention relates to the use of use of a long-acting insulin, in particular insulin glargine, in a method of reducing the risk of progression to type 2 diabetes in a patient, a method of reducing the risk of a new angina in a patient and a method of reducing the risk of a microvascular event in a patient comprising administering to said patient in need thereof a therapeutically effective dosage of a long acting insulin, wherein said therapeutically effective dosage of said long actin...

The invention relates to a method for treating type 2 diabetes patients, wherein insulin glargine is administered to the patient in an amount clinically tested to be safe and effective, wherein the type 2 diabetes is early type 2 diabetes, more particularly, wherein the insulin glargine is used as first-line drug.

The invention relates to a method for treating type 2 diabetes patients wherein insulin glargine is administered to the patient in an amount clinically tested to be safe and effective wherein the type 2 diabetes is early type 2 diabetes more particularly wherein the insulin glargine is used as first-line drug.

The invention relates to a method for treating type 2 diabetes patients wherein insulin glargine is administered to the patient in an amount clinically tested to be safe and effective wherein the type 2 diabetes is early type 2 diabetes more particularly wherein the insulin glargine is used as first-line drug.

This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.